Scott Gottlieb Quotes
We need to make sure that access to a curative drug doesn't become a yardstick by which poverty is eventually measured. Doing so requires a shared commitment between innovators and the insurance plans that are harder pressed to offer these advances to the poor.
Gottlieb, Scott. "Statement from FDA Commissioner Scott Gottlieb, M.D. on approval of first gene therapy in the U.S." U.S. Food and Drug Administration, 30 Aug. 2017.
Hai Thuong Lan Ong. Although half a world apart and a totally different culture compare the similarity of {42220}
In 1989 the company that owned the only drug that was helpful in treating AIDS had not yet made it available for children:
Criticizing restrictive health care policies regarding organ transplantation:
This quotation is an example of a tautology—a statement that simply repeats itself using different words. Critics of the George W. Bush administration turn to this and other quotations to illustrate the shallowness of the key leaders. The statement provides no knowledge and is self evident to most people. And this came from the most sophisticated budget official of the administration.
His company, Starbucks, was the first company to provide health insurance even for part time workers.
In order to obtain the support for Obamacare from the Pharmaceutical industry, Obama, agreed to take this power away from the government.
He, like so many Americans were shocked at the statistics on the relationship between earnings and infant mortality which does not exist in other industrial democracies.
Scott Gottlieb is an American physician and investor who served as the 23rd commissioner of the Food and Drug Administration (FDA) from 2017 until April 2019. He is presently a resident fellow at the conservative think tank the American Enterprise Institute (AEI), a partner at the venture capital firm New Enterprise Associates (NEA), a member of the board of directors of drug maker Pfizer, Inc, a member of the board of directors of Illumina, Inc., and a contributor to the cable financial news network CNBC. Before becoming FDA commissioner, he was a clinical assistant professor at New York University School of Medicine, the FDA deputy commissioner for medical and scientific affairs, a venture partner with New Enterprise Associates, a member of the policy board of the Leukemia & Lymphoma Society, a senior official at the Centers for Medicare and Medicaid Services, and a member of the Federal Health Information Technology Policy Committee, which advises the United States Department of Health and Human Services on healthcare information technology. He was previously a resident fellow at AEI from 2007 to 2017 prior to joining the FDA as commissioner in May 2017.
